Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics' stock has experienced a price decline, with a 33.05% decrease over the past year and a 14.6% fall since the beginning of 2026. The stock underwent a 1-for-20 reverse split on June 9th, 2025. The company announced a delay in initial clinical data for its BDC-4182 Phase 1 dose escalation study until the third quarter of 2026, attributed to modifying the trial protocol, and implemented a workforce reduction of approximately 50% to extend its cash runway into 2027. The company reported its third-quarter 2025 financial results on November 12, 2025, with collaboration revenue of $2.2 million and a reduced R&D expense. On March 12, 2026, Bolt Biotherapeutics reported its fourth-quarter and full-year 2025 financial results and also reported a Q1 2026 loss, but topped revenue estimates.

As a clinical-stage biopharmaceutical company, Bolt Biotherapeutics, Inc. does not have commercialized products, so demand seasonality is not applicable. The company's revenue primarily comes from collaboration agreements, and its financial performance is tied to clinical milestones and R&D expenses rather than seasonal consumer demand.

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, utilizing its Boltbody™ ISAC platform to activate myeloid cells for an anti-cancer immune response. The company's pipeline includes BDC-4182, a Boltbody™ ISAC clinical candidate targeting claudin 18.2, currently in Phase 1 trials for various cancers. BDC-3042, a dectin-2 agonist antibody program, has completed a Phase 1 dose-escalation trial for metastatic or unresectable solid tumors. The CEA ISAC program targets carcinoembryonic antigen for solid tumors, and the PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a TLR7/8 agonist. Bolt Biotherapeutics has collaborations with Genmab and Toray Industries.

Bolt Biotherapeutics, Inc. is headquartered in Redwood City, California, United States. The company's operations are based in the United States, with a global outlook through its international clinical trial network and potential strategic partnerships for development and commercialization.

Bolt Biotherapeutics' reputation has been shaped by its clinical progress and financial management. Presentations at the AACR Annual Meeting 2025 highlighted scientific advancements. However, the delay in clinical data for BDC-4182 and the workforce reduction in October 2025 likely negatively impacted investor confidence. Analyst ratings for BOLT are mixed, with a consensus rating of "Hold", based on some "Buy" and "Hold" ratings, and one "Sell" rating.

As of May 5, 2026, 86.70% of Bolt Biotherapeutics' stock is owned by institutional investors, with 24 institutional owners holding 633,610 shares. Major institutional owners include Sofinnova Investments, Inc., Pivotal bioVenture Partners Investment Advisor LLC, Vivo Capital, LLC, Nan Fung Group Holdings Ltd, Renaissance Technologies Llc, T3 Companies, LLC, Board of Trustees of The Leland Stanford Junior University, Pfizer Inc, BlackRock, Inc., and Geode Capital Management LLC. Major individual/insider owners include Vivo Capital VIII LLC, Holdings A. Novo, Edgar Engleman, James Healy, Sofinnova Venture Partners X LP, and Mahendra Shah.